

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

The Biotech Growth Trust PLC

BIOG – Biotech Growth Trust

1,004.00p ↑ 2.00 +0.2%

🇬🇧

EMS: 500

Market Cap

Enterprise Value

Revenue

Position in Market

£319.23m

£364.18m

£79.73m

— / 0

⚠️

StockRanks™ Unavailable

Financials · **Balanced** · Small Cap · n/a



Momentum

Relative Strength (%)	
1m	-4.78%
3m	-2.01%
6m	-2.54%
1y	+19.7%
Volume Change (%)	
10d / 3m	+49.1%
Price vs... (%)	
52w High	-6.21%
50d MA	-1.48%
200d MA	+2.49%

Growth & Value

Trailing 12m		Industry	Market
PE Ratio (ttm)	4.8		
PEG Ratio (ttm)	n/a		
EPS Growth (ttm)	n/a		
Dividend Yield (ttm)	0.00%		
Valuation (ttm)		Industry	Market
Price to Book Value	0.88		
Price to Tang. Book	0.88		
Price to Free Cashflow	n/a		
Price to Sales	4.00		
EV to EBITDA	4.87		

Shareholder Activity

Buy / Hold / Sell	
Institutions	
Directors	
Community	

Guru Screens

Biotech Growth Trust didn't qualify for any screens.

Quality

		Industry	Market
Return on Capital	20.7%		
Return on Equity	21.6%		
Operating Margin	93.77%		

Financial Summary

Fiscal Year End Mar		2019	2020	2021	2022	2023	2024	2025E	2026E	CAGR / Avg
Total Revenue	£m	26.7	66.0	226	-207	-36.2	79.7			24.5%
Operating Profit	£m	21.3	61.1	201	-202	-41.2	74.8			28.6%
Net Profit	£m	21.1	60.9	200	-202	-41.3	74.6			28.7%
EPS Reported	p	38.8	135	500	-488	-103	207			39.8%
EPS Normalised	p	38.8	135	500	-488	-103	207			39.8%
EPS Growth	%		+248	+271						
PE Ratio	x						4.84			
PEG										
Profitability										
Operating Margin	%	79.8	92.6	88.9			93.8			59.2%
ROA	%		14.6	38.2	-37.6	-10.5	19.3			
ROCE	%	5.21	16.7	33.3	-51.3	-12.5	20.7			2.03%
ROE	%		15.7	41.5	-40.7	-11.4	21.6			5.34%
Cashflow										
Op. Cashflow ps	p	-8.08	-8.34	-14.2	-29.3	-14.6	-11.8			
Capex ps	p	0.000	0.000	0.000	0.000	0.000	0.000			
Free Cashflow ps	p	-8.08	-8.34	-14.2	-29.3	-14.6	-11.8			
Dividends										
Ex: 4 Jul '01 / Pay: 30 Jul '01										
Dividend ps	p	0.000	0.000	0.000	0.000	0.000	0.000			
Dividend Growth	%									
Dividend Yield	%							0.000	0.000	
Dividend Cover	x									
Balance Sheet										
Cash etc	£m			1.50	0.000	2.77	2.13			
Working Capital	£m	-22.3	-33.1	-41.8	-33.2	-26.9	-33.4			

Health Trend (F-Score)

5/9

0123456789

Bankruptcy Risk (Z2-Score)

9.54

DistressCautiousSafe

Earnings Manipulation Risk (M-Score)

n/a

Other Ratios

Leverage (ttm)	Total	- Intang	+ Pension
Gross Gearing %	13.0	13.0	13.0
Net Gearing %	12.44	12.44	12.4
Cash / Assets %	0.52		0.5
Liquidity (ttm)			
Curr. Ratio			0.33
Quick Ratio			0.33
Interest Cov.			n/a
Efficiency (ttm)			
Asset Turnover			0.22
Recs Turnover			n/a
Stock Turnover			n/a


Fiscal Year End Mar		2019	2020	2021	2022	2023	2024	2025E	2026E	CAGR / Avg
Net Debt	£m	10.8	32.7	25.3	31.7	17.4	44.9			
Net Fixed Assets	£m	431	399	643	427	357	395			-1.75%
Book Value	£m	409	366	601	394	330	361			-2.44%
Average Shares	m	54	45	40	41	40	36			-8%
Book Value ps	p	787	932	1,446	958	853	1,079			6.52%

FINANCIAL BRIEF: For the fiscal year ended 31 March 2024, Biotech Growth Trust PLC revenues increased from -£36.2M to... [See more](#)

Recent History

Latest interim period vs. prior period		Industry	Market
Sales Growth	n/a		
EPS Growth	n/a		
3yr Compound Annual Growth Rate		Industry	Market
Sales CAGR	-29.29%		
EPS CAGR	-25.50%		
DPS CAGR	n/a		

Graphical History



Analyst Forecasts

Price Target: (0.00% below Price)	31st Mar 2025			31st Mar 2026		
	Net Profit (£)	EPS ()	DPS ()	Net Profit (£)	EPS ()	DPS ()
Est. Long Term Growth Rate:						
Consensus Estimate						
1m Change						
3m Change						

Analyst Consensus

0 brokers

Strong sell

Sell

Hold

Buy

Strong buy

EPS

Profile Summary

The Biotech Growth Trust PLC is a United Kingdom-based investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology co... [Read more](#)

Last Annual	Mar 31, 2024	Sector	Financials
Last Interim	Mar 31, 2024	Industry	Collective Investments
Incorporated	May 20, 1997	Index	FTSE All Share Index, FTSE All-share - Financials Price Return Index GBP End Of Day, FTSE All-share - Equity Investment Instruments Price Return Index GBP End Of Day, FTSE Smallcap Index
Public Since	Jun 23, 1997		
Ex Date	Jul 4, 2001		
Payment Date	Jul 30, 2001		
No. of Employees	n/a	Exchange	LSE Main Market
No. of Shareholders	n/a	Asset Category	Common Stock
		Shares in Issue	31,859,679
		Free Float	31,631,890 (99.29%)
		Eligible for	✓ ISAs ✓ SIPP

Address	25 Southampton Buildings, LONDON, WC2A 1AL, United Kingdom
Web	http://www.biotechgt.com/
Phone	+442030084910
Auditors	BDO LLP

BIOG Share Price Performance

Share Price	Volume	Bid - Ask	Low - High	Spread	1 week 3 month 6 month 1 year
1,004.00p	28,629	1,002.00p - 1,012.00p	1,002.00p - 1,010.00p	20bps	
Day's Change	Avg Volume	Open - Close	Range (12m)	Beta	
↑ 2.00 +0.2%	71,474	1,002.00p - 1,002.00p	715.00p - 1,068.36p	0.573	

Latest News for BIOG

32 minutes ago

[The Biotech Growth Trust PLC: Monthly Fact Sheet as at 30 September 2024](#)

Announcement

2:16 pm

[The Biotech Growth Trust PLC: Net Asset Value\(s\)](#)

Announcement

Yesterday 2:03 pm

[The Biotech Growth Trust PLC: Net Asset Value\(s\)](#)

Announcement

Wed, Oct 9, 2024

[The Biotech Growth Trust PLC: Net Asset Value\(s\)](#)

Announcement

Tue, Oct 8, 2024

[The Biotech Growth Trust PLC: Net Asset Value\(s\)](#)

Announcement

Upcoming Events for BIOG

Thursday, November 7th 2024

[Half Year 2025 Biotech Growth Trust PLC Earnings Release](#)

Similar to BIOG Compare

☐		Invesco Bond Income Plus Contrarian	59
☐		Literacy Capital Neutral	39
☐		Castelnau Turnaround	81
☐		Gryphon Capital Income Trust Neutral	67
☐		Horizon Technology Finance Value Trap	30
☐		CQS New City High Yield Fund Super Stock	92
☐		Ophir High Conviction Fund Neutral	69
☐		PennantPark Investment Neutral	62

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2024 © Stockopedia 2024, Refinitiv, Share Data Services.

- Important Information: To use Stockopedia, you must accept our Terms of Use, Privacy and Disclaimer & FSG. All financial services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.
- This communication cannot substitute for professional investment advice or independent factual verification. Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.
- Information in this commentary is current as at date prepared unless otherwise stated. However, please bear in mind that investments can go up or down in value, and that past performance is not a reliable indicator of future performance. Stockopedia looks for stocks that meet certain pre-defined criteria and presents the results to help users perform their own research. For more Important Information please refer to the Disclaimer section in the Stockopedia website.
- This communication may contain general Financial product advice. It has been prepared without taking into account your personal circumstances, and you should therefore consider its appropriateness in light of your objectives, financial circumstances and needs before acting on it.
- Company data is derived from data provided by Refinitiv
- Each company on Stockopedia is evaluated on the basis of hundreds of fundamental and technical metrics that measure a company's Quality, Value, Growth, and Momentum.
- QVM StockRanks™:
 - This measure equally blends the Quality, Value and Momentum ranks into a core metric, the StockRank.
- QualityRank™:
 - The QualityRank is based on a composite of carefully selected company factors based on the latest academic research into understanding 'Quality'. The factors used are inspired by the writings of Warren Buffett, Joseph Piotroski, Edward Altman and Messod Beneish, as well as recent papers from Robert Novy-Marx of the University of Chicago and National Bureau of Economic Research.
 - Each company in the market is ranked from 1 to 100 for each of these Quality Factors and a composite score is calculated as a weighted average of all these values. The QualityRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- ValueRank™:

- Our ValueRank is based on a composite of the following Value factors: Price to Book Value ; Price to Earnings ; Price to Free Cash Flow ; Dividend Yield % ; Price to Sales ; Earnings Yield %
- Consistent with the value investing philosophy, we use historic ratios for each of these metrics, rather than factoring in analyst forecasts. Each company in the market is ranked from 1 to 100 for each of these value ratios and a composite score is calculated as the weighted average of all valid values. The ValueRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- MomentumRank™:
 - The MomentumRank is based on a composite of the following Price and Estimate Momentum Factors.
 - Price Momentum Factors:
 - Proximity of current share price to the 52 week high ; 50 day vs 200 day moving averages ; 1 year Relative Strength of the share price vs the market ; 6 Month Relative Strength of the share price vs the market.
 - Earnings Momentum Factors:
 - EPS estimate upgrades within the last one month for next financial year ; EPS estimate upgrades within the last three months for this financial year ; EPS surprise percentage based on the latest reported financials ; Scaled earnings surprise based on the standard deviation of the original Consensus forecast ; Consensus broker recommendation upgrade over the last month
 - Each company in the market is ranked from 1 to 100 for each of these momentum ratios and a composite score is calculated as a weighted average of all valid values. The MomentumRank is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
 - When a company has no broker coverage we cannot calculate earnings momentum. As a result the Momentum Rank is calculated using price momentum factors alone.